Dive Brief:

潜水简介：

Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer without their disease worsening than those who got the typical care alone in a Phase 3 trial, the

在标准治疗中加入辉瑞公司的抗癌药物Braftovi，与在3期试验中单独接受典型治疗的患者相比，患有某种形式的大肠癌的患者寿命更长，疾病不会恶化

company said Monday

该公司周一表示

.

.

The result confirms earlier research from the study, called Breakwater, which had shown that trial volunteers receiving Braftovi were

这一结果证实了这项名为防波堤的研究的早期研究，该研究表明，接受Braftovi的试验志愿者

significantly more likely

可能性更大

to see their tumors shrink or disappear. Those data were used to support an

看到他们的肿瘤缩小或消失。这些数据被用来支持

accelerated U.S. clearance

加速美国清关

for Braftovi in colorectal cancer in December.

12月，Braftovi在结直肠癌中的应用。

Pfizer has been

辉瑞公司

under pressure from investors

受到投资者的压力

to grow revenue amid plummeting sales for its COVID-19 treatments, and cancer drug research is one area it

在新型冠状病毒肺炎治疗和癌症药物研究销售额急剧下降的情况下增加收入是它的一个领域

hopes can pick up the slack

希望可以弥补不足

. Braftovi and the related drug Mektovi, which Pfizer acquired in a

.Braftovi和相关药物Mektovi，辉瑞公司在a

2019 deal for Array BioPharma

2019年Array BioPharma交易

, generated

，已生成

$437 million in sales

销售额4.37亿美元

through the first nine months of 2024. Pfizer reports full-year earnings on Tuesday.

截至2024年前9个月。辉瑞公司将于周二公布全年收益。

Dive Insight:

潜水洞察：

Braftovi is a targeted medicine aimed at a particular mutation, V600E, to the BRAF gene. BRAF mutations occur in about

Braftovi是一种针对BRAF基因特定突变V600E的靶向药物。BRAF突变发生在大约

10% of people with colorectal cancer

10%的结直肠癌患者

, and the V600E is the most common among them.

，而V600E是其中最常见的。

A regimen of Braftovi and Mektovi is already approved in skin and lung cancers. In colorectal tumors, the drug is used in advanced disease with a drug called cetuximab. Those two are prescribed alongside chemotherapy in the frontline setting under the speedy clearance issued in December.

Braftovi和Mektovi的方案已被批准用于皮肤癌和肺癌。在结直肠肿瘤中，该药物与一种名为西妥昔单抗的药物一起用于晚期疾病。根据12月发布的快速批准，这两种药物与化疗一起在前线使用。

Pfizer acquired Braftovi and Mektovi in an $11.4 billion buyout of Array BioPharma in 2019. At the time, the two drugs were only cleared for melanoma. Pfizer broadened use to other tumors afterward, but they still only generate modest revenue compared to other cancer drugs in the company’s portfolio.

2019年，辉瑞以114亿美元收购了Array BioPharma，收购了Braftovi和Mektovi。当时，这两种药物仅被清除用于黑色素瘤。之后，辉瑞将其应用范围扩大到其他肿瘤，但与该公司投资组合中的其他抗癌药物相比，它们仍然只能产生适度的收入。

The new results revealed on Monday could boost those numbers, though, as Pfizer claimed, without revealing specific details, that Braftovi helped delay tumor progression and extend the lives of colorectal cancer patients. .

。。

Since the Array deal, Pfizer has shifted away from targeted small-molecule drugs for cancer and towards biologics. Antibody-drug conjugates, such as those acquired in

自Array交易以来，辉瑞已从针对癌症的小分子药物转向生物制剂。抗体-药物偶联物，例如在

a $43 billion deal for Seagen

以430亿美元收购Seagen

, are a focus and part of a plan to have biologics account for 65% of its oncology revenue by 2030 compared to only 6% in 2023.

，是到2030年生物制剂占其肿瘤学收入65%的计划的重点和组成部分，而2023年只有6%。

Patents for two of Pfizer’s biggest sellers in cancer,

辉瑞公司两个最大的癌症销售商的专利，

Xtandi and Ibrance

Xtandi 和 Ibrance

, expire in 2027.

，2027年到期。